Rieske FeS Inhibitors
Rieske FeS inhibitors are a class of chemical compounds that specifically target and inhibit the function of Rieske iron-sulfur (FeS) proteins, which are key components of the mitochondrial electron transport chain (ETC) and other related biochemical pathways. Rieske FeS proteins contain a unique iron-sulfur cluster that is essential for their role in facilitating electron transfer within the ETC, particularly in complex III, also known as the cytochrome bc1 complex. This complex is crucial for the transfer of electrons from ubiquinol to cytochrome c, a process that is integral to the generation of the proton gradient across the mitochondrial inner membrane. This gradient drives ATP synthesis, the primary energy currency in cells. By inhibiting Rieske FeS proteins, researchers can disrupt the electron transport chain, leading to a cessation of ATP production and providing a valuable tool for studying mitochondrial function and bioenergetics.
In research, Rieske FeS inhibitors are used to explore the intricacies of mitochondrial respiration and the broader implications of electron transport disruption on cellular metabolism. By blocking the function of Rieske FeS proteins, scientists can investigate the effects on mitochondrial membrane potential, reactive oxygen species (ROS) production, and the overall efficiency of oxidative phosphorylation. These inhibitors are particularly useful for studying the role of mitochondrial dysfunction in various cellular processes, including apoptosis, metabolic regulation, and the response to oxidative stress. Additionally, Rieske FeS inhibitors allow researchers to delve into the structural and functional relationships within the cytochrome bc1 complex and how alterations in electron flow impact the entire ETC. Through these studies, the use of Rieske FeS inhibitors provides deep insights into the fundamental mechanisms of cellular respiration, the critical role of mitochondria in energy production, and the consequences of impaired electron transport on cellular health and function.
SEE ALSO...
Items 1 to 10 of 11 total
Display:
| Product Name | CAS # | Catalog # | QUANTITY | Price | Citations | RATING |
|---|---|---|---|---|---|---|
Actinomycin D | 50-76-0 | sc-200906 sc-200906A sc-200906B sc-200906C sc-200906D | 5 mg 25 mg 100 mg 1 g 10 g | $74.00 $243.00 $731.00 $2572.00 $21848.00 | 53 | |
Actinomycin D binds to the DNA helix, specifically at the transcription initiation complex, obstructing RNA polymerase movement. This blockage would consequently downregulate Rieske FeS expression by halting its transcription process. | ||||||
Cycloheximide | 66-81-9 | sc-3508B sc-3508 sc-3508A | 100 mg 1 g 5 g | $41.00 $84.00 $275.00 | 127 | |
Cycloheximide disrupts eukaryotic protein synthesis by targeting the ribosomal translocation step, leading to premature termination. This can result in a broad decrease in protein levels, including the synthesis of Rieske FeS. | ||||||
5-Azacytidine | 320-67-2 | sc-221003 | 500 mg | $280.00 | 4 | |
As a nucleoside analogue, 5-Azacytidine incorporates into RNA and DNA and can cause hypomethylation of DNA. This demethylation can lead to the silencing of genes, potentially including the downregulation of those encoding Rieske FeS. | ||||||
α-Amanitin | 23109-05-9 | sc-202440 sc-202440A | 1 mg 5 mg | $269.00 $1050.00 | 26 | |
α-Amanitin, a potent inhibitor of RNA polymerase II, directly leads to the cessation of mRNA elongation, including the mRNA for Rieske FeS, thereby reducing its protein expression levels. | ||||||
Puromycin | 53-79-2 | sc-205821 sc-205821A | 10 mg 25 mg | $166.00 $322.00 | 436 | |
Puromycin causes premature termination of protein synthesis by mimicking an aminoacyl-tRNA, leading to a decrease in overall protein levels, including the inhibition of Rieske FeS protein synthesis. | ||||||
Trichostatin A | 58880-19-6 | sc-3511 sc-3511A sc-3511B sc-3511C sc-3511D | 1 mg 5 mg 10 mg 25 mg 50 mg | $152.00 $479.00 $632.00 $1223.00 $2132.00 | 33 | |
Trichostatin A inhibits histone deacetylase activity, which increases acetylation of histones, causing chromatin relaxation. This process can lead to selective downregulation or silencing of gene expression, including that for Rieske FeS. | ||||||
Retinoic Acid, all trans | 302-79-4 | sc-200898 sc-200898A sc-200898B sc-200898C | 500 mg 5 g 10 g 100 g | $66.00 $325.00 $587.00 $1018.00 | 28 | |
Retinoic acid binds to retinoic acid receptors, altering the transcription of downstream genes. This binding can result in decreased expression of target genes, including those encoding Rieske FeS. | ||||||
Rapamycin | 53123-88-9 | sc-3504 sc-3504A sc-3504B | 1 mg 5 mg 25 mg | $63.00 $158.00 $326.00 | 233 | |
Rapamycin inhibits the mTOR signaling pathway, which is essential for cell growth and protein synthesis. Inhibition of this pathway can lead to reduced translation of many proteins, including possibly Rieske FeS. | ||||||
Sodium Butyrate | 156-54-7 | sc-202341 sc-202341B sc-202341A sc-202341C | 250 mg 5 g 25 g 500 g | $31.00 $47.00 $84.00 $222.00 | 19 | |
Sodium butyrate, a short-chain fatty acid, inhibits histone deacetylase, which can cause hyperacetylation of histones and alter gene expression profiles. This alteration may include the downregulation of the gene encoding Rieske FeS. | ||||||
Spironolactone | 52-01-7 | sc-204294 | 50 mg | $109.00 | 3 | |
Spironolactone, by antagonizing aldosterone receptors, can lead to transcriptional changes in gene expression. This antagonist action may result in the decreased expression of genes, including the one for Rieske FeS. | ||||||